In 2023, Hong Kong has become a hub for international biotechnology companies, with at least 17 establishing operations, including several setting up Asia-Pacific headquarters. The city’s strengths in technology, global accessibility, and cross-border research opportunities, particularly within the Northern Metropolis innovation zone, are major draws. Companies like Swiss firm Quant Biomarkers and French OncoNex-Remunity Therapeutics are expanding their research bases in Hong Kong, highlighting its role as a gateway to the Greater Bay Area’s vast market. As interest in biotech continues to grow, Invest Hong Kong anticipates the number of new companies could reach 30 to 40 by the end of the year.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.chinadailyasia.com/article/632679
